loteprednol

(redirected from Alrex)
Also found in: Wikipedia.

loteprednol

 [lo″tĕ-pred´nol]
a corticosteroid applied topically to the conjunctiva in the treatment of seasonal allergic conjunctivitis, postoperative inflammation, and ocular inflammatory disorders.

loteprednol

/lo·te·pred·nol/ (lo″tĕ-pred´nol) a corticosteroid applied topically to the conjunctiva in the treatment of seasonal allergic conjunctivitis, postoperative inflammation, and ocular inflammatory disorders.

loteprednol

[lo′tĕpred′nol]
a corticosteroid applied topically to the conjunctiva in the treatment of seasonal allergic conjunctivitis, postoperative inflammation, and ocular inflammatory disorders.
References in periodicals archive ?
Susan also worked for B+L as the head of pharmaceutical sales and commercial operations where she launched their first branded pharmaceutical products including Lotemax and Alrex.
Under the terms of the agreement, both the Pfizer and Bausch & Lomb sales forces will promote Xalatan, Alrex, Lotemax, Zylet and besifloxacin (subject to FDA approval).
As with other ophthalmic corticosteroids, Alrex is contraindicated in most viral diseases of the corneas and conjunctiva and in mycobacterial and fungal diseases of the eye.
It is gratifying that our collaborative development of our loteprednol etabonate business with Bausch & Lomb that produced two earlier successful proprietary anti-inflammatory products, Lotemax and Alrex, has culminated in the commercialization of Zylet.
Ocuvite, ReNu MultiPlus, Boston Simplus, PureVision, Alaway, Lotemax, Zylet and Alrex are trademarks of Bausch & Lomb Incorporated.
Opthalmic Pharmaceutical Markets Include: Visudyne, Macugen, Restasis, Acular, Acular LS, Voltaren, Nevanac, Xibrom, Patanol, Zaditor, Emadine, Alomide, Pred Mild, Opticom, Alocril, Elestat, Crolom, Alrex, Optivar, Alamast, Livostin and Vasocon
Under the terms of the transaction, Pharmos received from Bausch & Lomb approximately $25 million in cash for the sale of Lotemax and Alrex, and will receive an amount estimated at approximately $14 million for LE-T, a third product in advanced clinical development, upon its approval by the FDA, the exact amount of which will be determined based on the actual approval date.
7 million from the proceeds of the sale of Lotemax and Alrex in return for his consent to Pharmos' assignment of its rights under the license agreement to Bausch & Lomb, and will also pay the patent owner a portion of the LE-T sale proceeds and a portion of its milestone payment.
According to IMS Health data, during the 2001 second quarter, the number of prescriptions written for Lotemax, an ophthalmic anti-inflammatory, increased 35%, and the number written for Alrex, an anti-allergy drug, increased 17%, compared to the 2000 second quarter.
The Company expects to report its second quarter 2001 revenues of Lotemax and Alrex together with its financial results in early August.
Lotemax and Alrex are products from the Company's more mature technology platform for ophthalmic drugs and are marketed by the Company's ophthalmic program marketing partner, Bausch & Lomb Pharmaceuticals, a division of Bausch & Lomb Incorporated.
market introduction at the end of 1998, more than 500,000 prescriptions have been written for Alrex and more than 900,000 prescriptions have been written for Lotemax.